fda compounding glp-1 enforcement news Escalates Against Compounded Marketing semaglutide compounding fda enforcement news

Semaglutide has received FDA approval for distinct clinical indications based on formulation and dosing regimen, reflecting its versatility as a GLP-1 receptor agonist

Keywords Bretylium Trade Name: generic Drug Class: Antiarrhythmic Mechanism of Action: (after an initial phase of causing the release of catecholamines) Interferes with the neuronal release of catecholamines Bretylium also lengthens the duration and effective refractory period in heart tissue (a Class III effect), an effect that is most pronounced in ischemic cells (which have shortened action potential durations) Indications: No longer available in the United States Previously used for attempted resuscitation from ventricular fibrillation after lidocaine and cardioversion have failed Side Effects: Precipitation of cardiac arrhythmias at the onset of drug therapy due to its ability to cause the initial release of catecholamines (when used as an antiarrhythmic)

Nutrients 12(6):1790

A., Aldini, G., & Derave, W